Lupin Launches Generic Tobramycin Inhalation Solution

Pharma major Lupin announced the launch of its Tobramycin Inhalation Solution USP, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa. Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of approximately USD 99 million in the US (IQVIA MAT April 2018). – Medical Buyer Bureau

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.